Integra Lifesciences Holdings Corp (IART) valuation
Integra Lifesciences Holdings P/E ratio history
Integra Lifesciences Holdings trades at 79.7 times its earnings over the last twelve months and 5.4 times the earnings analysts expect over the next twelve. At its last 8 fiscal year ends its P/E ranged from 26.0 (year to Dec 2022) to 100.5 (year to Dec 2019), with a median of 48.7.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Dec 31, 2025 | $12.42 | -$6.74 | n/m | 5.4 |
| Dec 31, 2024 | $22.68 | -$0.09 | n/m | 9.1 |
| Dec 31, 2023 | $43.55 | $0.84 | 51.9 | — |
| Dec 31, 2022 | $56.07 | $2.16 | 26.0 | — |
| Dec 31, 2021 | $66.99 | $1.98 | 33.8 | 19.9 |
| Dec 31, 2020 | $64.92 | $1.58 | 41.1 | — |
| Dec 31, 2019 | $58.28 | $0.58 | 100.5 | — |
| Dec 31, 2018 | $45.10 | $0.72 | 62.6 | — |
| Dec 31, 2017 | $47.86 | $0.82 | 58.4 | — |
| Dec 31, 2016 | $42.90 | $0.94 | 45.6 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Integra Lifesciences Holdings valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| Integra Lifesciences HoldingsIART | $992M | 79.7 | 5.4 | 0.6 |
| SavaraSVRA | $988M | — | — | — |
| HealthstreamHSTM | $985M | 46.8 | 41.7 | 3.1 |
| IradimedIRMD | $980M | 41.0 | 32.4 | 11.4 |
| CeribellCBLL | $1.01B | — | — | 9.9 |
| Oric PharmaceuticalsORIC | $957M | — | — | — |
| Rigel PharmaceuticalsRIGL | $949M | 3.0 | 12.1 | 3.4 |
| Si BoneSIBN | $942M | — | — | 4.4 |
| HarrowHROW | $1.05B | — | 17.7 | 3.8 |
| Peer median | 41.0 | 25.0 | 4.1 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: IART financials · IART returns
No forecast, no recommendation. This page describes Integra Lifesciences Holdings Corp from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.